Another radiation restenosis treatment tested :
This article was originally published in Clinica
Theragenics, a US company that makes the Theraseed prostate brachytherapy device, is to test its palladium-103 technology on animal models of coronary restenosis. The Buford, Georgia-based company has signed an agreement with the Atlanta Cardiovascular Research Institute to conduct a two-phase animal study, due to begin next month. The first phase will aim to determine whether a catheter-based Pd-103 source can inhibit restenosis, while the second will test stent-based Pd-103 devices. Theragenics is the latest in a long line of companies trying to exploit the anti-restenotic properties of various types of radiation sources.
You may also be interested in...
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.
As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.